Laura James
Concepts (571)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acetaminophen | 63 | 2025 | 277 | 12.040 |
Why?
| | Analgesics, Non-Narcotic | 28 | 2025 | 117 | 5.080 |
Why?
| | Drug Overdose | 17 | 2024 | 163 | 2.970 |
Why?
| | Liver | 25 | 2025 | 1154 | 2.870 |
Why?
| | Liver Failure, Acute | 13 | 2024 | 56 | 2.380 |
Why?
| | Hepatocytes | 16 | 2018 | 190 | 2.300 |
Why?
| | Liver Regeneration | 9 | 2019 | 47 | 1.830 |
Why?
| | MicroRNAs | 5 | 2020 | 385 | 1.280 |
Why?
| | Alanine Transaminase | 17 | 2023 | 120 | 1.210 |
Why?
| | Male | 89 | 2025 | 26652 | 1.140 |
Why?
| | Adolescent | 47 | 2025 | 6681 | 1.140 |
Why?
| | Proton Pump Inhibitors | 7 | 2024 | 86 | 1.080 |
Why?
| | Cytochrome P-450 CYP2E1 | 4 | 2020 | 111 | 1.080 |
Why?
| | Acetylcysteine | 13 | 2019 | 103 | 1.080 |
Why?
| | Mitochondria, Liver | 10 | 2015 | 69 | 1.050 |
Why?
| | Child | 44 | 2025 | 7147 | 1.000 |
Why?
| | Oxidative Stress | 12 | 2023 | 809 | 0.980 |
Why?
| | Cytochrome P-450 CYP3A | 3 | 2020 | 78 | 0.980 |
Why?
| | Humans | 107 | 2025 | 52114 | 0.940 |
Why?
| | Chromatography, High Pressure Liquid | 10 | 2016 | 335 | 0.860 |
Why?
| | Child, Preschool | 29 | 2024 | 4001 | 0.850 |
Why?
| | Female | 68 | 2025 | 28055 | 0.830 |
Why?
| | Cytokines | 8 | 2012 | 621 | 0.820 |
Why?
| | Attitude | 2 | 2021 | 70 | 0.810 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2012 | 62 | 0.800 |
Why?
| | Animals | 42 | 2025 | 13332 | 0.800 |
Why?
| | Asthma | 4 | 2022 | 314 | 0.780 |
Why?
| | Proteins | 4 | 2016 | 347 | 0.760 |
Why?
| | Rape | 1 | 2022 | 16 | 0.750 |
Why?
| | Vitamin D Deficiency | 1 | 2022 | 46 | 0.740 |
Why?
| | Crime Victims | 1 | 2022 | 46 | 0.710 |
Why?
| | Sex Offenses | 1 | 2022 | 77 | 0.680 |
Why?
| | Mice | 30 | 2025 | 5877 | 0.670 |
Why?
| | Health Facilities | 1 | 2021 | 39 | 0.670 |
Why?
| | Cysteine | 7 | 2024 | 50 | 0.650 |
Why?
| | Inflammation | 3 | 2020 | 641 | 0.650 |
Why?
| | Naphthalenes | 9 | 2018 | 120 | 0.630 |
Why?
| | Cytochrome P-450 CYP1A2 | 4 | 2020 | 39 | 0.630 |
Why?
| | Indoles | 9 | 2018 | 276 | 0.630 |
Why?
| | Health Services Accessibility | 2 | 2021 | 438 | 0.630 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2011 | 187 | 0.620 |
Why?
| | Liver Diseases | 4 | 2023 | 82 | 0.620 |
Why?
| | Bronchoconstriction | 1 | 2019 | 6 | 0.600 |
Why?
| | Mitochondria | 2 | 2020 | 421 | 0.590 |
Why?
| | 2-Pyridinylmethylsulfinylbenzimidazoles | 4 | 2018 | 18 | 0.580 |
Why?
| | Aspartate Aminotransferases | 8 | 2015 | 50 | 0.570 |
Why?
| | Bronchodilator Agents | 1 | 2019 | 75 | 0.550 |
Why?
| | Radius | 1 | 2018 | 27 | 0.550 |
Why?
| | Immunoassay | 1 | 2016 | 23 | 0.510 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 4 | 2014 | 76 | 0.510 |
Why?
| | Mice, Inbred C57BL | 16 | 2025 | 1872 | 0.510 |
Why?
| | Serum | 1 | 2016 | 32 | 0.510 |
Why?
| | Dose-Response Relationship, Drug | 12 | 2019 | 1368 | 0.500 |
Why?
| | Imines | 4 | 2025 | 16 | 0.500 |
Why?
| | Anti-Bacterial Agents | 6 | 2023 | 796 | 0.500 |
Why?
| | Gastroesophageal Reflux | 4 | 2018 | 48 | 0.500 |
Why?
| | Benzoquinones | 4 | 2025 | 33 | 0.500 |
Why?
| | Young Adult | 17 | 2023 | 4307 | 0.480 |
Why?
| | Infant | 21 | 2022 | 3660 | 0.480 |
Why?
| | Cystic Fibrosis | 1 | 2018 | 155 | 0.470 |
Why?
| | Lung | 1 | 2019 | 488 | 0.460 |
Why?
| | Reactive Nitrogen Species | 3 | 2015 | 23 | 0.460 |
Why?
| | Keratin-18 | 2 | 2021 | 14 | 0.460 |
Why?
| | Proliferating Cell Nuclear Antigen | 4 | 2019 | 68 | 0.450 |
Why?
| | HMGB1 Protein | 2 | 2021 | 21 | 0.450 |
Why?
| | Bile Acids and Salts | 1 | 2015 | 81 | 0.450 |
Why?
| | Mass Spectrometry | 4 | 2014 | 293 | 0.440 |
Why?
| | Tyrosine | 4 | 2007 | 91 | 0.440 |
Why?
| | Mice, Inbred Strains | 7 | 2019 | 163 | 0.440 |
Why?
| | Isoniazid | 1 | 2014 | 28 | 0.430 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 123 | 0.420 |
Why?
| | Adult | 24 | 2025 | 14095 | 0.420 |
Why?
| | Carnitine | 1 | 2014 | 68 | 0.410 |
Why?
| | Disease Models, Animal | 7 | 2020 | 1467 | 0.410 |
Why?
| | Autoantibodies | 1 | 2014 | 120 | 0.400 |
Why?
| | Trifluoperazine | 1 | 2012 | 6 | 0.390 |
Why?
| | Sensitivity and Specificity | 9 | 2016 | 871 | 0.380 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 1148 | 0.380 |
Why?
| | Viperidae | 1 | 2012 | 5 | 0.380 |
Why?
| | Crotalid Venoms | 1 | 2012 | 8 | 0.380 |
Why?
| | Antivenins | 1 | 2012 | 9 | 0.380 |
Why?
| | Immunoglobulin Fragments | 1 | 2012 | 14 | 0.380 |
Why?
| | Snake Bites | 1 | 2012 | 14 | 0.370 |
Why?
| | Anti-Ulcer Agents | 3 | 2007 | 21 | 0.370 |
Why?
| | Echinomycin | 1 | 2011 | 6 | 0.370 |
Why?
| | Hepatitis, Viral, Human | 2 | 2024 | 10 | 0.360 |
Why?
| | Prospective Studies | 12 | 2024 | 2424 | 0.360 |
Why?
| | Cannabinoids | 5 | 2013 | 104 | 0.350 |
Why?
| | Middle Aged | 18 | 2024 | 13028 | 0.350 |
Why?
| | Half-Life | 6 | 2019 | 87 | 0.350 |
Why?
| | Enzyme Inhibitors | 5 | 2019 | 371 | 0.350 |
Why?
| | Necrosis | 6 | 2019 | 169 | 0.350 |
Why?
| | Spider Venoms | 1 | 2011 | 6 | 0.350 |
Why?
| | Hospitalization | 4 | 2017 | 739 | 0.350 |
Why?
| | Hypersensitivity | 1 | 2012 | 81 | 0.350 |
Why?
| | Phosphoric Diester Hydrolases | 1 | 2011 | 45 | 0.340 |
Why?
| | Indocyanine Green | 1 | 2010 | 29 | 0.340 |
Why?
| | Arkansas | 8 | 2025 | 2016 | 0.330 |
Why?
| | Students | 2 | 2023 | 227 | 0.330 |
Why?
| | Macrolides | 3 | 2022 | 17 | 0.320 |
Why?
| | Methamphetamine | 3 | 2013 | 190 | 0.310 |
Why?
| | Models, Biological | 7 | 2024 | 731 | 0.310 |
Why?
| | Central Nervous System Stimulants | 3 | 2013 | 199 | 0.310 |
Why?
| | Triazoles | 3 | 2022 | 113 | 0.300 |
Why?
| | Metabolomics | 3 | 2015 | 151 | 0.300 |
Why?
| | Protein Binding | 5 | 2017 | 665 | 0.290 |
Why?
| | Homeostasis | 3 | 2020 | 205 | 0.280 |
Why?
| | Chemokines | 2 | 2010 | 78 | 0.280 |
Why?
| | Research Subjects | 2 | 2019 | 53 | 0.280 |
Why?
| | Community-Based Participatory Research | 2 | 2021 | 199 | 0.270 |
Why?
| | Chemokine CCL2 | 2 | 2005 | 65 | 0.270 |
Why?
| | Glutathione | 5 | 2025 | 303 | 0.270 |
Why?
| | Poisoning | 2 | 2006 | 21 | 0.270 |
Why?
| | Interleukin-6 | 3 | 2012 | 274 | 0.260 |
Why?
| | Area Under Curve | 8 | 2019 | 182 | 0.260 |
Why?
| | Interleukin-8 | 3 | 2012 | 86 | 0.260 |
Why?
| | Pandemics | 2 | 2022 | 579 | 0.260 |
Why?
| | Tandem Mass Spectrometry | 6 | 2018 | 249 | 0.260 |
Why?
| | Signal Transduction | 5 | 2019 | 1699 | 0.250 |
Why?
| | Caustics | 1 | 2006 | 5 | 0.250 |
Why?
| | Burns, Chemical | 1 | 2006 | 9 | 0.250 |
Why?
| | Cell Death | 4 | 2020 | 169 | 0.250 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2006 | 3 | 0.250 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 24 | 0.250 |
Why?
| | Cross-Sectional Studies | 3 | 2022 | 1665 | 0.250 |
Why?
| | Infant, Premature | 4 | 2016 | 327 | 0.240 |
Why?
| | Antidotes | 4 | 2011 | 27 | 0.240 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 1000 | 0.240 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2005 | 38 | 0.230 |
Why?
| | Liver Function Tests | 2 | 2002 | 48 | 0.230 |
Why?
| | Predictive Value of Tests | 5 | 2016 | 939 | 0.230 |
Why?
| | Reactive Oxygen Species | 3 | 2015 | 421 | 0.230 |
Why?
| | Infant, Newborn | 10 | 2018 | 2859 | 0.230 |
Why?
| | Peroxynitrous Acid | 2 | 2007 | 33 | 0.230 |
Why?
| | Cytochrome P-450 Enzyme System | 3 | 2015 | 191 | 0.220 |
Why?
| | Universities | 2 | 2023 | 172 | 0.220 |
Why?
| | Up-Regulation | 4 | 2018 | 459 | 0.220 |
Why?
| | Immunohistochemistry | 3 | 2012 | 975 | 0.210 |
Why?
| | Ion Channels | 1 | 2004 | 70 | 0.210 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 2 | 2015 | 34 | 0.210 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2024 | 53 | 0.210 |
Why?
| | Gastric Acidity Determination | 1 | 2003 | 12 | 0.210 |
Why?
| | Biotransformation | 4 | 2015 | 86 | 0.210 |
Why?
| | Aminoglycosides | 1 | 2023 | 20 | 0.210 |
Why?
| | Chromatography, Liquid | 6 | 2018 | 239 | 0.210 |
Why?
| | Glucuronosyltransferase | 3 | 2017 | 121 | 0.210 |
Why?
| | Diagnosis, Differential | 4 | 2024 | 1031 | 0.200 |
Why?
| | Medication Adherence | 1 | 2024 | 132 | 0.200 |
Why?
| | Administration, Oral | 7 | 2018 | 453 | 0.200 |
Why?
| | Pilot Projects | 4 | 2021 | 712 | 0.190 |
Why?
| | Membrane Glycoproteins | 1 | 2003 | 238 | 0.190 |
Why?
| | Designer Drugs | 2 | 2013 | 22 | 0.190 |
Why?
| | Granzymes | 2 | 2020 | 11 | 0.190 |
Why?
| | Aged | 7 | 2024 | 10142 | 0.190 |
Why?
| | Vitamins | 1 | 2022 | 65 | 0.190 |
Why?
| | Cell Line | 4 | 2017 | 1018 | 0.190 |
Why?
| | Digestive System | 1 | 2002 | 13 | 0.190 |
Why?
| | Pneumonia, Bacterial | 1 | 2022 | 30 | 0.190 |
Why?
| | Community-Acquired Infections | 1 | 2022 | 42 | 0.190 |
Why?
| | Obesity | 2 | 2022 | 1183 | 0.190 |
Why?
| | Vitamin D | 1 | 2022 | 90 | 0.180 |
Why?
| | Retrospective Studies | 9 | 2024 | 6610 | 0.180 |
Why?
| | Gastrointestinal Agents | 1 | 2002 | 39 | 0.180 |
Why?
| | Phosphatidic Acids | 2 | 2019 | 8 | 0.180 |
Why?
| | Parents | 1 | 2025 | 334 | 0.180 |
Why?
| | United States | 7 | 2022 | 5168 | 0.180 |
Why?
| | Photography | 1 | 2021 | 31 | 0.180 |
Why?
| | Microsomes, Liver | 4 | 2015 | 184 | 0.180 |
Why?
| | Anti-Infective Agents | 2 | 2013 | 106 | 0.180 |
Why?
| | Sexual Behavior | 1 | 2022 | 125 | 0.170 |
Why?
| | Metabolic Clearance Rate | 5 | 2018 | 67 | 0.170 |
Why?
| | Dried Blood Spot Testing | 2 | 2018 | 5 | 0.170 |
Why?
| | Oxidation-Reduction | 6 | 2023 | 326 | 0.170 |
Why?
| | Gastrointestinal Diseases | 1 | 2002 | 126 | 0.170 |
Why?
| | Healthcare Disparities | 1 | 2024 | 296 | 0.170 |
Why?
| | Bayes Theorem | 3 | 2012 | 120 | 0.170 |
Why?
| | Aged, 80 and over | 4 | 2021 | 3382 | 0.160 |
Why?
| | Heart Arrest | 1 | 2022 | 135 | 0.160 |
Why?
| | Substance-Related Disorders | 3 | 2022 | 609 | 0.160 |
Why?
| | Hydroxyurea | 1 | 2020 | 29 | 0.160 |
Why?
| | Polymorphism, Genetic | 2 | 2018 | 182 | 0.160 |
Why?
| | Brain | 3 | 2025 | 1311 | 0.160 |
Why?
| | Histamine H2 Antagonists | 3 | 2005 | 26 | 0.160 |
Why?
| | Recombinant Proteins | 4 | 2018 | 492 | 0.160 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 196 | 0.160 |
Why?
| | Lipids | 1 | 2020 | 159 | 0.150 |
Why?
| | Binding Sites | 2 | 2017 | 375 | 0.150 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2019 | 11 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 608 | 0.150 |
Why?
| | Prothrombin Time | 3 | 2005 | 18 | 0.150 |
Why?
| | Time Factors | 5 | 2013 | 2970 | 0.150 |
Why?
| | Mice, Knockout | 4 | 2011 | 893 | 0.150 |
Why?
| | Glycerol-3-Phosphate O-Acyltransferase | 1 | 2019 | 4 | 0.150 |
Why?
| | Carbachol | 1 | 2019 | 26 | 0.150 |
Why?
| | ortho-Aminobenzoates | 1 | 2019 | 6 | 0.150 |
Why?
| | Stress, Physiological | 1 | 2020 | 184 | 0.150 |
Why?
| | Organ Culture Techniques | 1 | 2019 | 44 | 0.150 |
Why?
| | Respiratory Hypersensitivity | 1 | 2019 | 17 | 0.150 |
Why?
| | Child, Hospitalized | 1 | 2019 | 32 | 0.150 |
Why?
| | Liver Cirrhosis | 1 | 2021 | 243 | 0.150 |
Why?
| | Drug Administration Schedule | 4 | 2021 | 374 | 0.150 |
Why?
| | Case-Control Studies | 3 | 2018 | 1193 | 0.150 |
Why?
| | Disclosure | 1 | 2019 | 40 | 0.150 |
Why?
| | Bacterial Infections | 2 | 2017 | 96 | 0.150 |
Why?
| | Body Weight | 3 | 2018 | 526 | 0.150 |
Why?
| | Seroepidemiologic Studies | 3 | 2023 | 44 | 0.150 |
Why?
| | Cannabidiol | 1 | 2019 | 43 | 0.140 |
Why?
| | Research Personnel | 1 | 2019 | 72 | 0.140 |
Why?
| | Oropharynx | 2 | 2009 | 13 | 0.140 |
Why?
| | Ampicillin | 1 | 2018 | 5 | 0.140 |
Why?
| | Hepatitis, Autoimmune | 1 | 2018 | 27 | 0.140 |
Why?
| | Albuterol | 1 | 2019 | 57 | 0.140 |
Why?
| | Protein Biosynthesis | 2 | 2017 | 265 | 0.140 |
Why?
| | Information Dissemination | 1 | 2019 | 85 | 0.140 |
Why?
| | HSP72 Heat-Shock Proteins | 1 | 2018 | 9 | 0.140 |
Why?
| | Treatment Outcome | 6 | 2019 | 5456 | 0.140 |
Why?
| | Health Status Disparities | 1 | 2021 | 216 | 0.140 |
Why?
| | Education, Nonprofessional | 1 | 2017 | 8 | 0.140 |
Why?
| | Phosphatidate Phosphatase | 1 | 2018 | 23 | 0.140 |
Why?
| | Human Experimentation | 1 | 2017 | 11 | 0.140 |
Why?
| | Mass Screening | 1 | 2021 | 356 | 0.140 |
Why?
| | Sirtuin 1 | 1 | 2017 | 29 | 0.140 |
Why?
| | Sulfonamides | 1 | 2019 | 132 | 0.140 |
Why?
| | Teicoplanin | 1 | 2017 | 4 | 0.140 |
Why?
| | Teaching Materials | 1 | 2017 | 31 | 0.140 |
Why?
| | Patient Participation | 1 | 2018 | 68 | 0.140 |
Why?
| | 3' Untranslated Regions | 1 | 2017 | 55 | 0.130 |
Why?
| | Rural Population | 2 | 2021 | 571 | 0.130 |
Why?
| | Health Services Research | 1 | 2018 | 152 | 0.130 |
Why?
| | Absorptiometry, Photon | 1 | 2018 | 159 | 0.130 |
Why?
| | Reading | 1 | 2017 | 73 | 0.130 |
Why?
| | Severity of Illness Index | 3 | 2024 | 1035 | 0.130 |
Why?
| | Substance Abuse Detection | 2 | 2022 | 89 | 0.130 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 528 | 0.130 |
Why?
| | Electrochemical Techniques | 1 | 2016 | 9 | 0.130 |
Why?
| | Anthropometry | 2 | 2015 | 101 | 0.130 |
Why?
| | Comprehension | 1 | 2017 | 113 | 0.130 |
Why?
| | Nuclear Proteins | 1 | 2018 | 246 | 0.130 |
Why?
| | Age Factors | 3 | 2015 | 1125 | 0.120 |
Why?
| | Saliva | 1 | 2016 | 56 | 0.120 |
Why?
| | Vitamin A | 1 | 2016 | 16 | 0.120 |
Why?
| | Liver Failure | 1 | 2016 | 22 | 0.120 |
Why?
| | Amphetamine | 2 | 2013 | 37 | 0.120 |
Why?
| | Nitric Oxide Synthase Type I | 2 | 2015 | 10 | 0.120 |
Why?
| | Injections, Intravenous | 3 | 2012 | 133 | 0.120 |
Why?
| | Point-of-Care Systems | 1 | 2016 | 65 | 0.120 |
Why?
| | Blood Proteins | 2 | 2006 | 84 | 0.120 |
Why?
| | Caffeine | 1 | 2016 | 64 | 0.120 |
Why?
| | Blood Pressure Monitors | 1 | 2015 | 10 | 0.120 |
Why?
| | Biomedical Research | 1 | 2019 | 262 | 0.120 |
Why?
| | Taurodeoxycholic Acid | 1 | 2015 | 6 | 0.120 |
Why?
| | Glycodeoxycholic Acid | 1 | 2015 | 6 | 0.120 |
Why?
| | Glycochenodeoxycholic Acid | 1 | 2015 | 6 | 0.120 |
Why?
| | Guanidines | 1 | 2015 | 28 | 0.120 |
Why?
| | Keratin-8 | 1 | 2015 | 3 | 0.120 |
Why?
| | Styrene | 1 | 2015 | 9 | 0.120 |
Why?
| | Bone Density | 1 | 2018 | 394 | 0.120 |
Why?
| | Delayed-Action Preparations | 2 | 2012 | 55 | 0.120 |
Why?
| | Prodrugs | 2 | 2012 | 35 | 0.120 |
Why?
| | Breast Neoplasms | 1 | 2024 | 1199 | 0.120 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2015 | 72 | 0.120 |
Why?
| | Solid Phase Extraction | 2 | 2013 | 14 | 0.120 |
Why?
| | Tablets | 3 | 2013 | 32 | 0.120 |
Why?
| | Cross-Over Studies | 2 | 2012 | 238 | 0.110 |
Why?
| | Immunity, Innate | 1 | 2016 | 112 | 0.110 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2014 | 2 | 0.110 |
Why?
| | Nitrates | 2 | 2011 | 30 | 0.110 |
Why?
| | Administration, Intravenous | 3 | 2019 | 73 | 0.110 |
Why?
| | Cells, Cultured | 4 | 2017 | 1568 | 0.110 |
Why?
| | Famotidine | 2 | 2005 | 11 | 0.110 |
Why?
| | Discriminant Analysis | 1 | 2014 | 27 | 0.110 |
Why?
| | Environmental Pollutants | 1 | 2015 | 106 | 0.110 |
Why?
| | Least-Squares Analysis | 1 | 2014 | 44 | 0.110 |
Why?
| | Superoxide Dismutase | 2 | 2011 | 120 | 0.100 |
Why?
| | Urinalysis | 1 | 2014 | 33 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2012 | 392 | 0.100 |
Why?
| | Cannabis | 2 | 2019 | 150 | 0.100 |
Why?
| | Wounds, Stab | 1 | 2013 | 5 | 0.100 |
Why?
| | Cyclosporine | 2 | 2011 | 67 | 0.100 |
Why?
| | Fentanyl | 1 | 2014 | 39 | 0.100 |
Why?
| | Basal Ganglia | 1 | 2013 | 25 | 0.100 |
Why?
| | Neck Injuries | 1 | 2013 | 21 | 0.100 |
Why?
| | Benzoflavones | 1 | 2013 | 3 | 0.100 |
Why?
| | Sulfaphenazole | 1 | 2013 | 4 | 0.100 |
Why?
| | Nonlinear Dynamics | 2 | 2012 | 17 | 0.100 |
Why?
| | Self-Injurious Behavior | 1 | 2013 | 30 | 0.100 |
Why?
| | Kinetics | 4 | 2018 | 616 | 0.100 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2012 | 504 | 0.100 |
Why?
| | Cohort Studies | 3 | 2019 | 1541 | 0.100 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2012 | 17 | 0.100 |
Why?
| | Mycophenolic Acid | 1 | 2012 | 19 | 0.100 |
Why?
| | Myoglobin | 1 | 2013 | 25 | 0.100 |
Why?
| | Receptors, Phospholipase A2 | 1 | 2012 | 14 | 0.100 |
Why?
| | Neurotoxicity Syndromes | 1 | 2013 | 46 | 0.100 |
Why?
| | Indicators and Reagents | 1 | 2012 | 36 | 0.100 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2012 | 25 | 0.100 |
Why?
| | Dinoprostone | 1 | 2012 | 49 | 0.100 |
Why?
| | Permeability | 1 | 2012 | 67 | 0.100 |
Why?
| | Flushing | 1 | 2012 | 5 | 0.100 |
Why?
| | Piperacillin | 1 | 2012 | 24 | 0.090 |
Why?
| | Fasting | 1 | 2012 | 75 | 0.090 |
Why?
| | T-Lymphocytes | 1 | 2014 | 316 | 0.090 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2012 | 19 | 0.090 |
Why?
| | Antibodies, Viral | 2 | 2023 | 110 | 0.090 |
Why?
| | Blood Specimen Collection | 1 | 2012 | 35 | 0.090 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2012 | 106 | 0.090 |
Why?
| | Erythema | 1 | 2012 | 38 | 0.090 |
Why?
| | Insulin | 1 | 2014 | 484 | 0.090 |
Why?
| | Metronidazole | 1 | 2012 | 28 | 0.090 |
Why?
| | Exanthema | 1 | 2012 | 32 | 0.090 |
Why?
| | Pruritus | 1 | 2012 | 44 | 0.090 |
Why?
| | Cardiopulmonary Bypass | 1 | 2012 | 92 | 0.090 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 204 | 0.090 |
Why?
| | Ketamine | 1 | 2012 | 59 | 0.090 |
Why?
| | Heart Septal Defects, Ventricular | 1 | 2012 | 45 | 0.090 |
Why?
| | Vancomycin | 1 | 2012 | 86 | 0.090 |
Why?
| | Neutropenia | 1 | 2012 | 113 | 0.090 |
Why?
| | Sex Factors | 1 | 2014 | 731 | 0.090 |
Why?
| | Cellulitis | 1 | 2011 | 10 | 0.090 |
Why?
| | Receptor, Cannabinoid, CB1 | 1 | 2012 | 123 | 0.090 |
Why?
| | Neuroprotective Agents | 1 | 2012 | 101 | 0.090 |
Why?
| | Nitroimidazoles | 1 | 2011 | 16 | 0.090 |
Why?
| | Anemia, Hemolytic | 1 | 2011 | 11 | 0.090 |
Why?
| | Rhabdomyolysis | 1 | 2011 | 11 | 0.090 |
Why?
| | Hair | 1 | 2011 | 29 | 0.090 |
Why?
| | Hypertension | 2 | 2015 | 565 | 0.090 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 166 | 0.090 |
Why?
| | Coloring Agents | 1 | 2010 | 68 | 0.080 |
Why?
| | Brain Injuries | 1 | 2012 | 158 | 0.080 |
Why?
| | Kidney Transplantation | 1 | 2012 | 196 | 0.080 |
Why?
| | Muscular Diseases | 1 | 2011 | 63 | 0.080 |
Why?
| | Interleukin-10 | 2 | 2012 | 81 | 0.080 |
Why?
| | Immunoblotting | 1 | 2010 | 118 | 0.080 |
Why?
| | Liver Circulation | 1 | 2010 | 21 | 0.080 |
Why?
| | Sodium Oxybate | 1 | 2009 | 11 | 0.080 |
Why?
| | Butylene Glycols | 1 | 2009 | 14 | 0.080 |
Why?
| | Coma | 1 | 2009 | 17 | 0.080 |
Why?
| | Play and Playthings | 1 | 2009 | 15 | 0.080 |
Why?
| | Blood Pressure | 1 | 2012 | 535 | 0.080 |
Why?
| | Linear Models | 2 | 2012 | 290 | 0.080 |
Why?
| | Kidney Diseases | 1 | 2012 | 229 | 0.080 |
Why?
| | Databases as Topic | 1 | 2009 | 38 | 0.080 |
Why?
| | Environmental Exposure | 1 | 2011 | 214 | 0.080 |
Why?
| | Foreign Bodies | 1 | 2009 | 66 | 0.080 |
Why?
| | Immunosuppressive Agents | 1 | 2011 | 249 | 0.080 |
Why?
| | Incidence | 1 | 2012 | 1070 | 0.070 |
Why?
| | Blood Chemical Analysis | 1 | 2008 | 26 | 0.070 |
Why?
| | Drug Compounding | 1 | 2008 | 26 | 0.070 |
Why?
| | Cesium | 1 | 2008 | 8 | 0.070 |
Why?
| | Chlorides | 1 | 2008 | 43 | 0.070 |
Why?
| | DNA | 1 | 2011 | 543 | 0.070 |
Why?
| | Probability | 1 | 2008 | 171 | 0.070 |
Why?
| | Macrophages | 2 | 2017 | 360 | 0.070 |
Why?
| | Registries | 2 | 2024 | 629 | 0.070 |
Why?
| | Analgesics, Opioid | 1 | 2014 | 587 | 0.070 |
Why?
| | Chloroform | 1 | 2007 | 5 | 0.070 |
Why?
| | Models, Statistical | 1 | 2009 | 231 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 2 | 2012 | 1518 | 0.070 |
Why?
| | Free Radical Scavengers | 2 | 2011 | 24 | 0.070 |
Why?
| | Infusions, Intravenous | 2 | 2023 | 218 | 0.070 |
Why?
| | Sulfuric Acids | 1 | 2006 | 8 | 0.060 |
Why?
| | Electrocardiography | 1 | 2008 | 279 | 0.060 |
Why?
| | Acute Kidney Injury | 1 | 2011 | 384 | 0.060 |
Why?
| | Aerobiosis | 1 | 2006 | 13 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2007 | 554 | 0.060 |
Why?
| | Genotype | 3 | 2018 | 563 | 0.060 |
Why?
| | Emergency Medicine | 1 | 2006 | 49 | 0.060 |
Why?
| | Hepatitis C, Chronic | 2 | 2018 | 86 | 0.060 |
Why?
| | Toxicity Tests | 1 | 2006 | 57 | 0.060 |
Why?
| | Reproducibility of Results | 3 | 2015 | 1214 | 0.060 |
Why?
| | Antioxidants | 2 | 2023 | 257 | 0.060 |
Why?
| | Phosphorylation | 2 | 2019 | 523 | 0.060 |
Why?
| | Cell Nucleus | 1 | 2006 | 188 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 234 | 0.060 |
Why?
| | Mice, Transgenic | 2 | 2018 | 560 | 0.060 |
Why?
| | Metabolic Detoxication, Phase II | 2 | 2017 | 11 | 0.060 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2004 | 18 | 0.060 |
Why?
| | Child Abuse | 1 | 2006 | 139 | 0.050 |
Why?
| | Receptors, Progesterone | 1 | 2024 | 66 | 0.050 |
Why?
| | Kupffer Cells | 1 | 2003 | 12 | 0.050 |
Why?
| | Computer Simulation | 2 | 2017 | 292 | 0.050 |
Why?
| | Glutathione Disulfide | 1 | 2003 | 38 | 0.050 |
Why?
| | Single-Blind Method | 2 | 2015 | 116 | 0.050 |
Why?
| | Risk Assessment | 1 | 2008 | 1339 | 0.050 |
Why?
| | Models, Chemical | 2 | 2015 | 66 | 0.050 |
Why?
| | Superoxides | 1 | 2003 | 46 | 0.050 |
Why?
| | Papillomavirus Vaccines | 1 | 2025 | 69 | 0.050 |
Why?
| | Pyruvic Acid | 1 | 2023 | 20 | 0.050 |
Why?
| | Receptors, Estrogen | 1 | 2024 | 131 | 0.050 |
Why?
| | Alanine | 1 | 2023 | 43 | 0.050 |
Why?
| | Omeprazole | 1 | 2003 | 16 | 0.050 |
Why?
| | Ischemia | 1 | 2024 | 154 | 0.050 |
Why?
| | Mixed Function Oxygenases | 1 | 2003 | 25 | 0.050 |
Why?
| | Injections, Intraperitoneal | 1 | 2003 | 56 | 0.050 |
Why?
| | Prognosis | 3 | 2015 | 2093 | 0.050 |
Why?
| | Safety | 1 | 2003 | 80 | 0.050 |
Why?
| | Immunoenzyme Techniques | 1 | 2003 | 135 | 0.050 |
Why?
| | Oxygen | 1 | 2006 | 333 | 0.050 |
Why?
| | Hydrogen Peroxide | 1 | 2003 | 119 | 0.050 |
Why?
| | Radiographic Image Enhancement | 1 | 2003 | 30 | 0.050 |
Why?
| | Pediatrics | 1 | 2006 | 291 | 0.050 |
Why?
| | Genetic Variation | 1 | 2024 | 224 | 0.050 |
Why?
| | Logistic Models | 2 | 2018 | 925 | 0.050 |
Why?
| | Tibial Fractures | 1 | 2003 | 33 | 0.050 |
Why?
| | Drug Interactions | 1 | 2003 | 201 | 0.050 |
Why?
| | Molecular Structure | 2 | 2013 | 315 | 0.050 |
Why?
| | Papillomavirus Infections | 1 | 2025 | 171 | 0.050 |
Why?
| | Vaccination | 1 | 2025 | 296 | 0.050 |
Why?
| | Liver Transplantation | 1 | 2024 | 167 | 0.050 |
Why?
| | Membrane Potential, Mitochondrial | 2 | 2015 | 41 | 0.050 |
Why?
| | Neoplasms | 1 | 2012 | 1288 | 0.050 |
Why?
| | Hydroxylation | 2 | 2012 | 64 | 0.050 |
Why?
| | Endothelium, Vascular | 1 | 2003 | 257 | 0.050 |
Why?
| | Glutamate Dehydrogenase | 1 | 2021 | 16 | 0.050 |
Why?
| | Nitric Oxide | 1 | 2003 | 234 | 0.050 |
Why?
| | Death, Sudden, Cardiac | 1 | 2022 | 59 | 0.040 |
Why?
| | Psychotropic Drugs | 1 | 2022 | 76 | 0.040 |
Why?
| | Databases, Factual | 1 | 2024 | 714 | 0.040 |
Why?
| | Uncertainty | 1 | 2021 | 44 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2023 | 742 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2025 | 503 | 0.040 |
Why?
| | Apoptosis | 1 | 2006 | 1117 | 0.040 |
Why?
| | Kidney Failure, Chronic | 1 | 2003 | 212 | 0.040 |
Why?
| | Gestational Age | 2 | 2012 | 418 | 0.040 |
Why?
| | Anti-Asthmatic Agents | 1 | 2020 | 33 | 0.040 |
Why?
| | Decision Making | 1 | 2002 | 277 | 0.040 |
Why?
| | Australia | 1 | 2019 | 90 | 0.040 |
Why?
| | Risk Factors | 3 | 2012 | 3922 | 0.040 |
Why?
| | Drug Synergism | 1 | 2019 | 148 | 0.040 |
Why?
| | Research Design | 1 | 2021 | 367 | 0.040 |
Why?
| | Tissue Distribution | 2 | 2013 | 172 | 0.040 |
Why?
| | Hepatitis Viruses | 1 | 2018 | 2 | 0.040 |
Why?
| | Qualitative Research | 1 | 2021 | 358 | 0.040 |
Why?
| | beta Catenin | 1 | 2019 | 103 | 0.040 |
Why?
| | Mallory Bodies | 1 | 2018 | 1 | 0.040 |
Why?
| | Metagenomics | 1 | 2018 | 40 | 0.040 |
Why?
| | Drug Dosage Calculations | 1 | 2018 | 11 | 0.040 |
Why?
| | Acute-Phase Reaction | 1 | 2018 | 8 | 0.040 |
Why?
| | Pregnancy | 1 | 2025 | 2658 | 0.030 |
Why?
| | DNA, Viral | 1 | 2018 | 138 | 0.030 |
Why?
| | RNA, Viral | 1 | 2018 | 124 | 0.030 |
Why?
| | Ethics, Research | 1 | 2017 | 39 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2018 | 82 | 0.030 |
Why?
| | Metabolic Networks and Pathways | 1 | 2018 | 90 | 0.030 |
Why?
| | Metabolic Detoxication, Phase I | 1 | 2017 | 11 | 0.030 |
Why?
| | Gas Chromatography-Mass Spectrometry | 2 | 2011 | 70 | 0.030 |
Why?
| | Rats | 2 | 2014 | 3146 | 0.030 |
Why?
| | MAP Kinase Signaling System | 1 | 2018 | 126 | 0.030 |
Why?
| | Gene Frequency | 1 | 2017 | 98 | 0.030 |
Why?
| | Glucuronides | 1 | 2017 | 48 | 0.030 |
Why?
| | Communication | 1 | 2019 | 254 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 231 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 174 | 0.030 |
Why?
| | Plant Extracts | 1 | 2019 | 194 | 0.030 |
Why?
| | Transfection | 1 | 2017 | 366 | 0.030 |
Why?
| | Residence Characteristics | 1 | 2017 | 158 | 0.030 |
Why?
| | Liver Diseases, Alcoholic | 1 | 2016 | 35 | 0.030 |
Why?
| | Oscillometry | 1 | 2015 | 7 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2017 | 197 | 0.030 |
Why?
| | Health Literacy | 1 | 2017 | 131 | 0.030 |
Why?
| | NAD | 1 | 2015 | 45 | 0.030 |
Why?
| | Diastole | 1 | 2015 | 68 | 0.030 |
Why?
| | Arm | 1 | 2015 | 47 | 0.030 |
Why?
| | Systole | 1 | 2015 | 74 | 0.030 |
Why?
| | Binding, Competitive | 1 | 2015 | 90 | 0.030 |
Why?
| | Observer Variation | 1 | 2015 | 131 | 0.030 |
Why?
| | Patient Safety | 1 | 2016 | 102 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2015 | 106 | 0.030 |
Why?
| | Substrate Specificity | 1 | 2015 | 197 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2019 | 1017 | 0.030 |
Why?
| | Suramin | 1 | 2014 | 10 | 0.030 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily B | 1 | 2014 | 3 | 0.030 |
Why?
| | Fas Ligand Protein | 1 | 2014 | 17 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 182 | 0.030 |
Why?
| | Antigens, Ly | 1 | 2014 | 8 | 0.030 |
Why?
| | Islets of Langerhans | 1 | 2014 | 26 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2015 | 200 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2014 | 61 | 0.030 |
Why?
| | Algorithms | 1 | 2018 | 663 | 0.030 |
Why?
| | Gene Silencing | 1 | 2014 | 120 | 0.030 |
Why?
| | Thiazolidinediones | 1 | 2014 | 81 | 0.030 |
Why?
| | Biological Availability | 2 | 2005 | 108 | 0.030 |
Why?
| | Pentanones | 1 | 2013 | 7 | 0.030 |
Why?
| | Glutathione Transferase | 1 | 2014 | 175 | 0.030 |
Why?
| | Capsules | 1 | 2013 | 29 | 0.030 |
Why?
| | Powders | 1 | 2013 | 25 | 0.030 |
Why?
| | Paper | 1 | 2013 | 16 | 0.030 |
Why?
| | Methylamines | 1 | 2013 | 20 | 0.030 |
Why?
| | Ethanol | 1 | 2016 | 335 | 0.030 |
Why?
| | Benzodioxoles | 1 | 2013 | 39 | 0.020 |
Why?
| | Pyrrolidines | 1 | 2013 | 63 | 0.020 |
Why?
| | Body Temperature Regulation | 1 | 2013 | 29 | 0.020 |
Why?
| | Hallucinogens | 1 | 2013 | 57 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2013 | 192 | 0.020 |
Why?
| | Heterozygote | 1 | 2012 | 91 | 0.020 |
Why?
| | Cell Survival | 1 | 2014 | 596 | 0.020 |
Why?
| | Pyrans | 1 | 2012 | 16 | 0.020 |
Why?
| | Drug Resistance | 1 | 2012 | 68 | 0.020 |
Why?
| | Placebo Effect | 1 | 2012 | 16 | 0.020 |
Why?
| | Amine Oxidase (Copper-Containing) | 1 | 2012 | 3 | 0.020 |
Why?
| | Fever | 1 | 2013 | 111 | 0.020 |
Why?
| | Prescription Drugs | 1 | 2012 | 40 | 0.020 |
Why?
| | Interleukin-3 | 1 | 2012 | 12 | 0.020 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2012 | 24 | 0.020 |
Why?
| | Intention to Treat Analysis | 1 | 2012 | 30 | 0.020 |
Why?
| | Histamine | 1 | 2012 | 24 | 0.020 |
Why?
| | Glucose | 1 | 2014 | 358 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 866 | 0.020 |
Why?
| | Dopamine | 1 | 2013 | 169 | 0.020 |
Why?
| | Protein Precursors | 1 | 2012 | 42 | 0.020 |
Why?
| | Calcitonin | 1 | 2012 | 30 | 0.020 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2012 | 24 | 0.020 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2012 | 51 | 0.020 |
Why?
| | Population | 1 | 2012 | 8 | 0.020 |
Why?
| | Office Visits | 1 | 2012 | 44 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2012 | 123 | 0.020 |
Why?
| | Ligands | 1 | 2012 | 206 | 0.020 |
Why?
| | Hyperthermia, Induced | 1 | 2013 | 114 | 0.020 |
Why?
| | Expectorants | 1 | 2011 | 14 | 0.020 |
Why?
| | Risk | 1 | 2012 | 312 | 0.020 |
Why?
| | Central Nervous System | 1 | 2012 | 76 | 0.020 |
Why?
| | Glucuronic Acid | 1 | 2011 | 11 | 0.020 |
Why?
| | Creatinine | 1 | 2012 | 158 | 0.020 |
Why?
| | Monte Carlo Method | 1 | 2012 | 88 | 0.020 |
Why?
| | Microsomes | 1 | 2011 | 35 | 0.020 |
Why?
| | ROC Curve | 1 | 2012 | 250 | 0.020 |
Why?
| | Deuterium | 1 | 2011 | 47 | 0.020 |
Why?
| | Reference Standards | 1 | 2011 | 51 | 0.020 |
Why?
| | Syndrome | 1 | 2012 | 247 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2011 | 89 | 0.020 |
Why?
| | Birth Weight | 1 | 2012 | 128 | 0.020 |
Why?
| | Cytoplasm | 1 | 2011 | 93 | 0.020 |
Why?
| | Forensic Toxicology | 1 | 2011 | 4 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2012 | 152 | 0.020 |
Why?
| | Muscular Dystrophies | 1 | 2011 | 14 | 0.020 |
Why?
| | Hair Color | 1 | 2011 | 10 | 0.020 |
Why?
| | Spinal Muscular Atrophies of Childhood | 1 | 2011 | 9 | 0.020 |
Why?
| | Glucuronidase | 1 | 2011 | 47 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2011 | 91 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2012 | 600 | 0.020 |
Why?
| | Forecasting | 1 | 2012 | 152 | 0.020 |
Why?
| | Crime | 1 | 2011 | 27 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2011 | 124 | 0.020 |
Why?
| | Transaminases | 1 | 2011 | 11 | 0.020 |
Why?
| | Bilirubin | 1 | 2011 | 44 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2012 | 234 | 0.020 |
Why?
| | Blotting, Western | 1 | 2011 | 588 | 0.020 |
Why?
| | Intestines | 1 | 2011 | 154 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2012 | 718 | 0.020 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2011 | 152 | 0.020 |
Why?
| | Intestinal Mucosa | 1 | 2011 | 222 | 0.020 |
Why?
| | Child Development | 1 | 2012 | 201 | 0.020 |
Why?
| | Body Mass Index | 1 | 2013 | 699 | 0.020 |
Why?
| | Suction | 1 | 2009 | 23 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 1534 | 0.020 |
Why?
| | Alcohol Drinking | 1 | 2011 | 236 | 0.020 |
Why?
| | Eating | 1 | 2009 | 159 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 463 | 0.020 |
Why?
| | Kidney | 1 | 2013 | 713 | 0.020 |
Why?
| | Survival Rate | 1 | 2011 | 945 | 0.020 |
Why?
| | Alcoholism | 1 | 2011 | 237 | 0.020 |
Why?
| | Nitric Oxide Synthase | 1 | 2007 | 64 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2013 | 808 | 0.020 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2008 | 199 | 0.020 |
Why?
| | Liver Neoplasms | 1 | 2008 | 332 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2009 | 2282 | 0.010 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2003 | 28 | 0.010 |
Why?
| | Specialization | 1 | 2003 | 49 | 0.010 |
Why?
| | Medicine | 1 | 2003 | 51 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2003 | 460 | 0.010 |
Why?
| | Endopeptidases | 1 | 2002 | 63 | 0.010 |
Why?
|
|
James's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|